The top dose produced 20.9% average weight loss over 72 weeks and 20.2% in a direct comparison with semaglutides 13.7%. Its second receptor, GIP, separates tirzepatide from approved single-receptor GLP-1 drugs and helps explain the larger population-level weight loss. That 20.9% came from participants averaging about 105 kg at a BMI of 38, most of whom were sedentary
Age and Genetic Factors : As people age, their bodies naturally produce less intrinsic factor, reducing the ability to absorb B12 from food and supplements
The only human trial ever registered (NCT02637284) was cancelled in 2016 without publishing results
Flu like symptoms can last up to 24 hours when given IV
In a large Japanese cohort of over 7,000 healthy individuals living in an iodine-sufficient region, Yamada et al
Its best to speak with a healthcare professional, like a Midi clinician, to figure out the right path for you, your symptoms, and your health history